Quetiapine's effect on the SCL-90-R domains in patients with borderline personality disorder

Susanne S. Lee, Jeff Allen, Donald W. Black, Mary C. Zanarini, S. Charles Schulz

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


BACKGROUND: This study aimed to examine the impact of quetiapine on the symptom and distress domains measured by the Symptom Checklist-90-Revised (SCL-90-R) in patients with borderline personality disorder (BPD).

METHODS: Ninety-five participants meeting DSM-IV diagnostic criteria for BPD were randomly assigned to low-dosage (quetiapine, 150 mg/d; n = 33), moderate-dosage (quetiapine, 300 mg/d; n = 33), or placebo (n = 29). SCL-90-R was administered weekly over the course of an 8-week double-blind treatment phase. We used a mixed-effects model to analyze subscale scores of the SCL-90-R.

RESULTS: Results showed that both dosages of quetiapine were effective in reducing levels of overall psychological distress, interpersonal sensitivity, depression, and hostility compared with those who received placebo.

CONCLUSIONS: SCL-90-R can be a useful tool that would allow clinicians to collect information in addition to the DSM symptoms to better understand the diagnostic heterogeneity found in patients diagnosed with BPD.

Original languageEnglish (US)
Pages (from-to)4-10
Number of pages7
JournalAnnals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
Issue number1
StatePublished - Feb 1 2016


Dive into the research topics of 'Quetiapine's effect on the SCL-90-R domains in patients with borderline personality disorder'. Together they form a unique fingerprint.

Cite this